查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2095125

發炎性腸道疾病治療市場－全球市場預測（2026-2032年）

Inflammatory Bowel Disease Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，發炎性腸道疾病治療市場規模將成長至 294.7 億美元，複合年成長率為 4.99%。

主要市場統計數據
基準年 2025 209.5億美元
預計年份：2026年 219.5億美元
預測年份 2032 294.7億美元
複合年成長率 (%) 4.99%

鑑於潰瘍性大腸炎和克隆氏症對全球醫療保健系統帶來的日益沉重的臨床、社會和經濟負擔，發炎性腸道疾病 (IBD) 的治療正在迅速發展。 IBD 是一種慢性免疫介導性疾病，其特徵是反覆發作的腸道發炎、腸外症狀、生活品質下降，以及若疾病控制不佳，住院和手術風險增加。目前的治療策略越來越強調標靶治療、黏膜癒合、減少荷爾蒙用量的緩解、藥物監測以及反映疾病嚴重程度、治療史、共病、安全性以及患者意願的協作決策。

治療方案包括氨基水楊酸類藥物、皮質類固醇、免疫調節劑、腫瘤壞死因子、整合素、靶向白細胞介素通路的生物製藥製劑，以及新型小分子療法，例如Janus激酶抑製劑和鞘氨醇-1-磷酸受體調變器。除了藥物創新之外，營養支持、微生物組調查、微創手術、內視鏡監測、綜合心理健康護理以及支持藥物依從性的數位化工具也在不斷完善發炎性腸道疾病 (IBD) 的診療路徑。這標誌著 IBD 治療格局的變革性轉變。

發炎性腸道疾病（IBD）的治療格局正在經歷一場變革性的轉變，其驅動力包括早期療育、基於生物標記的決策、先進治療方案的拓展，以及更加注重長期緩解疾病而非短期症狀控制。臨床實務正從被動強化治療轉向主動監測，監測手段包括內視鏡檢查、糞鈣衛蛋白、C反應蛋白、截面影像學檢查以及檢驗的病患報告結局（PRO）。這種轉變有助於及時最佳化治療方案，減少對糖皮質激素的依賴，並提高緩解期的維持率。

另一個顯著的變化是生物相似藥的作用日益增強。這改善了許多醫療保健系統中患者獲得治療的機會，同時促進了基於價值的採購，並有助於在真實世界臨床人群中積累循證醫學證據。然而，這也使治療方案的選擇變得更加複雜，因為臨床醫生必須全面考慮給藥途徑、起效時間、免疫抗原性、感染風險、血栓性栓塞症風險、惡性腫瘤風險、妊娠計劃、疫苗接種情況以及患者依從性等因素。醫療保健的提供方式也在發生變化，多學科發炎性腸道疾病中心、藥劑師主導的監測、護理導航員、註冊營養師、結直腸外科醫生和行為醫學專家都在為協作式醫療服務做出貢獻。這些變化正在加強發炎性腸道疾病治療中更個人化和數據驅動的模式，無論是在資源豐富還是資源匱乏的環境中。

人工智慧（AI）對發炎性腸道疾病（IBD）治療的累積影響

人工智慧 (AI) 正透過決策支援、影像診斷、風險分層、臨床試驗最佳化和病患監測等方式，開始影響發炎性腸道疾病 (IBD) 的治療。目前正在研究利用 AI 驅動的內視鏡工具來支持對發炎、潰瘍、黏膜癒合和疾病活動度的標準化評估，有助於減少潰瘍性大腸炎和克隆氏症評估中觀察者間的差異。此外，研究人員也正在探索利用機器學習模型，透過整合實驗室指標、內視鏡檢查觀察、基因組資訊、微生物組訊號、用藥史和病人自述數據，來預測復發風險、對生物製藥和小分子藥物的反應、住院風險以及術後復發。

發炎性腸道疾病治療的關鍵區域見解

在亞太地區，都市化、飲食結構改變、診斷技術的進步以及專科醫生意識提升，使得中國、印度、日本、韓國、澳大利亞和東南亞等地的人們對潰瘍性大腸炎和克隆氏症的認知顯著增強，從而促使臨床醫生更加重視炎症性腸病（IBD）的治療。該地區的治療路徑因地而異，成熟醫療體系能夠獲得結構完善的生物製藥和先進的內視鏡設備，而發展中地區則面臨著成本效益和轉診方面的挑戰。生物相似藥、本地臨床指南、真實世界數據（REW）的廣泛應用以及學術胃腸病學網路的擴展，是改善治療可及性和最佳化治療的關鍵促進因素。

影響IBD治療可及性的關鍵團體見解

在東南亞國協，隨著主要城市胃腸病服務的擴展以及對潰瘍性大腸炎和克隆氏症症的認知提高，發炎性腸道疾病（IBD）的治療正朝著更系統化的方向發展。然而，該地區各地獲得先進治療的機會仍然不均衡，成本效益、診斷、醫生培訓、內視鏡服務以及本地指南的採納仍然是改善醫療保健的關鍵挑戰。在海灣合作理事會（GCC）國家，對三級醫療基礎設施、專科診所、先進療法和數位醫療系統的投資正在促進都市區IBD的診斷和管理，同時也凸顯了長期登記數據、藥物安全監測和標準化診療路徑的必要性。

主要國家發炎性腸道疾病治療趨勢

在美國，生物製藥、生物相似藥、小分子藥物、藥物監測、臨床試驗和多學科IBD中心在內的先進發炎性腸道疾病（IBD）治療方法已被廣泛採用，但保險覆蓋範圍和自付費用仍然是獲得醫療保健的重大障礙。在加拿大，重點在於基於指南的治療、轉診至專科醫生、透過省級報銷框架獲得生物製藥以及真實世界監測，並持續關注農村地區的等待時間和就醫便利性。墨西哥和巴西正在透過擴大胃腸病學專業規模、公私合營和完善診療路徑，以及提高對克隆氏症和潰瘍性大腸炎的認知，來加強IBD的診斷和治療，但報銷制度的差異和專科醫生的分佈仍然影響著患者的就醫。

為發炎性腸道疾病治療領域的領導者提供的實用建議

產業領導者應優先進行證據收集工作，以證明生物製劑和小分子藥物在真實世界發炎性腸道疾病（IBD）患者群體中，能夠有效改善持續緩解、減重類固醇用量、促進黏膜癒合、提高安全性、增強用藥依從性、延長治療持續時間並改善患者生活品質（QOL）。治療藥物研發者和醫療保健相關人員應投資於生物標記研究、伴隨診斷和預測分析，以最佳化生物製藥和小分子藥物的患者選擇。擴大生物相似藥教育、制定透明的過渡方案、加強醫病溝通以及進行藥物安全監測，有助於擴大藥物可近性並提升其公信力。

基於證據的發炎性腸道疾病調查方法

本執行摘要採用系統性的二手調查方法撰寫，重點在於與發炎性腸道疾病治療相關的、檢驗且有數據支持的資訊來源。研究途徑包括分析同行評審的醫學文獻、臨床實踐指南、監管安全資訊、公共衛生資料、疾病登記、藥物警戒參考資料以及真實世界數據（REW）出版物。尤其著重於與潰瘍性大腸炎、克隆氏症、治療路徑、先進療法、生物相似藥、診斷工具、監測策略、區域可近性趨勢、數位健康應用相關的、經科學檢驗的研究結果。

結論：IBD治療的未來方向

發炎性腸道疾病的治療正朝著更精準、以患者為中心和技術驅動的方向發展。標靶治療、先進生物製藥、口服小分子藥物、生物相似藥、藥物監測、多學科診療、真實世界數據以及新興人工智慧（AI）的融合，正在提升潰瘍性大腸炎和克隆氏症的長期管理能力。同時，診斷、經濟負擔、專科醫生診療、內視鏡檢查以及保險報銷等方面的差異，仍在區域和國家層面影響治療結果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 發炎性腸道疾病治療市場：依治療類型分類

  • 先進的治療方法
    • 基因治療
    • 微生物組調節器
    • 幹細胞療法
  • 生物製劑
    • 整合素受體拮抗劑
    • 白細胞介素抑制劑
    • TNF抑制劑
  • 小分子藥物
    • 氨基水楊酸類藥物
    • 皮質類固醇
    • 免疫抑制劑
  • 手術治療
    • 造口術
    • 切除
    • 狹窄成形術

第8章 發炎性腸道疾病治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服
  • 直腸給藥

第9章 發炎性腸道疾病治療市場：依製劑類型分類

  • 液體
    • 口服液
    • 暫停
  • 注射劑
  • 固態劑型
    • 咀嚼片
    • 緩釋片

第10章 發炎性腸道疾病治療市場：依應用領域分類

  • 克隆氏症
  • 病因不明的結腸炎
  • 潰瘍性大腸炎

第11章 發炎性腸道疾病治療市場：依最終使用者分類

  • 診所
  • 居家醫療
  • 醫院

第12章 發炎性腸道疾病治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 發炎性腸道疾病治療市場：依病患類型分類

  • 成年人口
  • 老年人
  • 兒童患者

第14章 發炎性腸道疾病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 發炎性腸道疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 發炎性腸道疾病治療市場：依國家分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Abivax
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • Entera Bio Ltd.
  • FutureGen Biopharmaceutical（Beijing）Co., Ltd.
  • GlaxoSmithKline PLC
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Morphic Therapeutic, Inc.
  • Nestle SA
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharma Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • TScan Therapeutics, Inc.
  • UCB SA
  • Viatris Inc.
  • Zealand Pharma A/S
Product Code: MRR-563BF1FCFF1E

The Inflammatory Bowel Disease Treatment Market is projected to grow by USD 29.47 billion at a CAGR of 4.99% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.95 billion
Estimated Year [2026] USD 21.95 billion
Forecast Year [2032] USD 29.47 billion
CAGR (%) 4.99%

Inflammatory bowel disease treatment is advancing rapidly as ulcerative colitis and Crohn's disease create a growing clinical, social, and economic burden on health systems worldwide. IBD is a chronic, immune-mediated disorder characterized by relapsing intestinal inflammation, extraintestinal manifestations, impaired quality of life, and elevated risks of hospitalization and surgery when disease control is inadequate. Current treatment strategies increasingly emphasize treat-to-target care, mucosal healing, steroid-sparing remission, therapeutic drug monitoring, and shared decision-making that reflects disease severity, prior treatment exposure, comorbidities, safety profile, and patient preferences.

The therapeutic landscape includes aminosalicylates, corticosteroids, immunomodulators, biologic therapies targeting tumor necrosis factor, integrins, interleukin pathways, and newer small-molecule therapies such as Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators. Alongside pharmacological innovation, nutrition support, microbiome research, minimally invasive surgery, endoscopic monitoring, mental health integration, and digital adherence tools are reshaping IBD care pathways. Transformative Shifts in the IBD Treatment Landscape

The IBD treatment landscape is undergoing transformative shifts driven by earlier intervention, biomarker-guided decision-making, expanding advanced therapy options, and a stronger focus on long-term disease modification rather than short-term symptom control. Clinical practice has moved beyond reactive escalation toward proactive monitoring using endoscopy, fecal calprotectin, C-reactive protein, cross-sectional imaging, and validated patient-reported outcomes. This shift supports timely therapy optimization, reduced corticosteroid dependency, and improved durability of remission.

Another major change is the broadening role of biosimilars, which has increased therapeutic access in many healthcare systems while encouraging value-based procurement and evidence generation in real-world populations. At the same time, treatment selection has become more complex as clinicians weigh route of administration, onset of action, immunogenicity, infection risk, thromboembolic warnings, malignancy considerations, pregnancy planning, vaccination status, and patient adherence. Care delivery is also changing, with multidisciplinary IBD centers, pharmacist-led monitoring, nurse navigators, dietitians, colorectal surgeons, and behavioral health professionals contributing to coordinated care. These shifts are reinforcing a more personalized, data-informed model of inflammatory bowel disease treatment across both high-resource and access-constrained settings.

Cumulative Impact of Artificial Intelligence on IBD Care

Artificial intelligence is beginning to influence inflammatory bowel disease treatment through decision support, imaging interpretation, risk stratification, clinical trial optimization, and patient monitoring. AI-enabled endoscopy tools are being studied to support standardized assessment of inflammation, ulceration, mucosal healing, and disease activity, helping reduce interobserver variability in ulcerative colitis and Crohn's disease evaluation. Machine learning models are also being explored to predict flare risk, likelihood of response to biologics or small molecules, hospitalization risk, and postoperative recurrence by integrating laboratory markers, endoscopy findings, genomics, microbiome signals, medication history, and patient-reported data.

The cumulative impact of artificial intelligence is most significant when AI augments clinical workflows rather than replacing clinician judgment. In practice, AI can help identify patients who may need earlier treatment escalation, flag adherence gaps, prioritize colonoscopy scheduling, and support remote monitoring programs through symptom tracking and digital biomarkers. However, evidence quality, external model validation, data representativeness, cybersecurity, explainability, and regulatory oversight remain essential. For IBD treatment stakeholders, responsible AI adoption requires clinically validated algorithms, interoperable electronic health records, robust governance, and bias mitigation to ensure that digital innovation improves outcomes without widening disparities.

Key Regional Insights Across IBD Treatment

Asia-Pacific is experiencing rising clinical attention to inflammatory bowel disease treatment as urbanization, dietary transition, improved diagnostics, and greater specialist awareness contribute to increased recognition of ulcerative colitis and Crohn's disease in China, India, Japan, South Korea, Australia, and Southeast Asia. Treatment pathways across the region vary widely, from highly structured biologic access and advanced endoscopy capacity in mature health systems to affordability and referral challenges in developing settings. Biosimilars, local clinical guidelines, increasing use of real-world evidence, and expanding academic gastroenterology networks are important drivers of access and treatment optimization.

North America remains one of the most advanced regions for IBD treatment adoption, supported by specialist networks, clinical trial infrastructure, therapeutic drug monitoring, biologic and small-molecule availability, patient registries, and patient advocacy. Care models in the United States and Canada increasingly emphasize treat-to-target strategies, insurance navigation, safety surveillance, shared decision-making, and multidisciplinary disease management. Latin America is strengthening inflammatory bowel disease treatment capacity through expanding gastroenterology expertise, greater recognition of disease burden, and broader access to advanced therapies in major urban centers, although uneven reimbursement, diagnostic delays, and geographic disparities continue to shape care delivery.

Europe demonstrates strong implementation of evidence-based IBD care, aided by harmonized clinical guidelines, established registries, biosimilar adoption, and structured reimbursement mechanisms in many countries. The region continues to prioritize comparative effectiveness, pharmacovigilance, therapeutic optimization, and cost-conscious access to biologics and small molecules. The Middle East is seeing rising demand for specialized IBD services, particularly in countries with advanced tertiary care systems and growing investment in digestive disease centers. Africa faces the greatest access constraints, with underdiagnosis, limited specialist availability, and variable access to endoscopy, imaging, pathology, and advanced therapies; however, improved disease awareness, medical training, and referral networks are gradually supporting more consistent inflammatory bowel disease diagnosis and treatment.

Key Group Insights Shaping IBD Treatment Access

ASEAN countries are progressing toward more structured inflammatory bowel disease treatment as gastroenterology capacity expands in major cities and awareness of ulcerative colitis and Crohn's disease improves. Access to advanced therapies remains uneven across the region, making affordability, diagnostics, physician training, endoscopy capacity, and local guideline adoption central to care improvement. GCC countries are investing in tertiary healthcare infrastructure, specialty clinics, advanced therapeutics, and digital health systems, supporting stronger IBD diagnosis and management in urban centers while also highlighting the need for long-term registry data, pharmacovigilance, and standardized care pathways.

The European Union plays a leading role in evidence-based IBD treatment through strong regulatory oversight, guideline implementation, biosimilar utilization, cross-border research collaboration, health technology assessment processes, and pharmacovigilance systems. BRICS countries represent diverse IBD treatment environments, combining high population scale with varied reimbursement structures, local manufacturing capabilities, and increasing interest in biologics, biosimilars, clinical training, and digital health solutions. The G7 countries generally demonstrate broad availability of advanced IBD therapies, robust clinical research activity, mature safety monitoring systems, and established specialty care models, although affordability and payer criteria continue to influence treatment sequencing. NATO member countries, many of which overlap with advanced healthcare economies, show strong adoption of standardized clinical protocols and specialty care networks, while disparities across member states underscore the importance of equitable access to inflammatory bowel disease treatment.

Key Country Insights in Inflammatory Bowel Disease Treatment

The United States shows high adoption of advanced inflammatory bowel disease treatment, including biologics, biosimilars, small molecules, therapeutic drug monitoring, clinical trials, and multidisciplinary IBD centers, although insurance authorization and out-of-pocket burden remain important care barriers. Canada emphasizes guideline-based care, specialist referral, biologic access through provincial reimbursement frameworks, and real-world monitoring, with ongoing attention to wait times and rural access. Mexico and Brazil are strengthening IBD diagnosis and treatment through expanding gastroenterology expertise, public-private care pathways, and greater recognition of Crohn's disease and ulcerative colitis, while variability in reimbursement and specialist distribution continues to influence patient access.

In Europe, the United Kingdom supports structured IBD care through national clinical guidance, specialist nursing roles, biologic stewardship, and patient-centered monitoring, while Germany benefits from strong specialist infrastructure, endoscopy capacity, clinical research participation, and access to advanced therapies. France maintains evidence-driven treatment pathways and safety surveillance, Italy and Spain continue to expand biologic and biosimilar adoption through regional healthcare systems, and Russia faces a more heterogeneous access environment influenced by geography, reimbursement, and specialty care availability. Across these countries, corticosteroid-sparing remission, mucosal healing, relapse prevention, and long-term safety remain central clinical priorities.

In Asia-Pacific, China is rapidly increasing IBD awareness and specialist capacity as diagnosis improves in urban hospitals and tertiary centers, while India faces a dual challenge of rising recognition and highly variable affordability across public and private settings. Japan has mature diagnostic and therapeutic infrastructure, strong clinical guideline adoption, extensive experience with advanced IBD treatments, and well-established monitoring practices. Australia combines specialist IBD centers, registry activity, biologic access, and telehealth-enabled care with a focus on remote services for geographically dispersed populations. South Korea demonstrates advanced endoscopy capacity, expanding biologic use, strong academic research, and digital health infrastructure that supports modern chronic disease management in inflammatory bowel disease.

Actionable Recommendations for IBD Treatment Leaders

Industry leaders should prioritize evidence generation that demonstrates durable remission, steroid reduction, mucosal healing, safety, adherence, treatment persistence, and patient quality-of-life outcomes in real-world IBD populations. Treatment developers and healthcare stakeholders should invest in biomarker research, companion diagnostics, and predictive analytics that improve patient selection for biologics and small molecules. Expanding biosimilar education, transparent switching protocols, clinician-patient communication, and pharmacovigilance can improve confidence while supporting broader access.

Healthcare systems should strengthen multidisciplinary IBD care models by integrating gastroenterologists, colorectal surgeons, nurses, pharmacists, dietitians, psychologists, radiologists, pathologists, and primary care providers. Digital monitoring programs should be designed around validated outcomes, privacy safeguards, and actionable escalation pathways rather than passive data collection. Industry leaders should also support equitable access strategies, including patient assistance, local manufacturing partnerships where appropriate, clinician training, and region-specific evidence. In parallel, organizations should prepare for responsible AI deployment by validating algorithms across diverse populations, establishing governance frameworks, and ensuring that AI outputs are interpretable, auditable, and clinically useful.

Research Methodology for Evidence-Based IBD Insights

This executive summary is developed using a structured secondary research methodology focused on verified, data-backed sources relevant to inflammatory bowel disease treatment. The research approach includes analysis of peer-reviewed medical literature, clinical practice guidelines, regulatory safety communications, public health resources, disease registries, pharmacovigilance references, and real-world evidence publications. Emphasis is placed on scientifically validated insights related to ulcerative colitis, Crohn's disease, treatment pathways, advanced therapies, biosimilars, diagnostic tools, monitoring strategies, regional access dynamics, and digital health applications.

The methodology applies thematic synthesis to identify consistent trends across clinical efficacy, safety, treatment sequencing, care delivery, patient access, and technology adoption. Regional, group, and country insights are interpreted through publicly available healthcare infrastructure indicators, reimbursement patterns, guideline maturity, specialist access, and documented therapeutic adoption patterns. No market sizing, market share estimation, or forecasting is included. The content is designed to support executive decision-making while maintaining clinical accuracy, and compliance with evidence-based reporting principles.

Conclusion: Future Direction of IBD Treatment

Inflammatory bowel disease treatment is entering a more precise, patient-centered, and technology-enabled phase. The convergence of treat-to-target care, advanced biologics, oral small molecules, biosimilars, therapeutic drug monitoring, multidisciplinary care, real-world evidence, and emerging artificial intelligence is improving the ability to manage ulcerative colitis and Crohn's disease over the long term. At the same time, disparities in diagnosis, affordability, specialist access, endoscopy capacity, and reimbursement continue to shape outcomes across regions and countries.

Sustainable progress will depend on responsible innovation, equitable access, stronger safety monitoring, and better integration of clinical, digital, and patient-reported data. Industry leaders that align product development, care models, and access strategies with measurable patient outcomes will be best positioned to support the evolving needs of the inflammatory bowel disease treatment ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Inflammatory Bowel Disease Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Advanced Therapies
    • 7.2.1. Gene Therapy
    • 7.2.2. Microbiome Modulators
    • 7.2.3. Stem Cell Therapy
  • 7.3. Biologics
    • 7.3.1. Integrin Receptor Antagonists
    • 7.3.2. Interleukin Inhibitors
    • 7.3.3. TNF Inhibitors
  • 7.4. Small Molecule Drugs
    • 7.4.1. Aminosalicylates
    • 7.4.2. Corticosteroids
    • 7.4.3. Immunosuppressants
  • 7.5. Surgical Procedures
    • 7.5.1. Ostomy
    • 7.5.2. Resection
    • 7.5.3. Strictureplasty

8. Inflammatory Bowel Disease Treatment Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Injectable
    • 8.2.1. Intravenous
    • 8.2.2. Subcutaneous
  • 8.3. Oral
  • 8.4. Rectal

9. Inflammatory Bowel Disease Treatment Market, by Formulation Type

  • 9.1. Introduction
  • 9.2. Liquid Formulations
    • 9.2.1. Oral Solutions
    • 9.2.2. Suspensions
  • 9.3. Parenteral Preparations
  • 9.4. Solid Dosage Forms
    • 9.4.1. Chewable Tablets
    • 9.4.2. Extended Release Tablets

10. Inflammatory Bowel Disease Treatment Market, by Application

  • 10.1. Introduction
  • 10.2. Crohns Disease
  • 10.3. Indeterminate Colitis
  • 10.4. Ulcerative Colitis

11. Inflammatory Bowel Disease Treatment Market, by End-User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Home Care Settings
  • 11.4. Hospitals

12. Inflammatory Bowel Disease Treatment Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Inflammatory Bowel Disease Treatment Market, by Patient Type

  • 13.1. Introduction
  • 13.2. Adult Population
  • 13.3. Geriatric Population
  • 13.4. Pediatric Population

14. Inflammatory Bowel Disease Treatment Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Inflammatory Bowel Disease Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Inflammatory Bowel Disease Treatment Market, by Country

  • 16.1. United States
  • 16.2. Germany
  • 16.3. China
  • 16.4. United Kingdom
  • 16.5. India
  • 16.6. Japan
  • 16.7. Russia
  • 16.8. Brazil
  • 16.9. Canada
  • 16.10. Italy
  • 16.11. Mexico
  • 16.12. France
  • 16.13. Spain
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. AbbVie Inc.
  • 18.3. Abivax
  • 18.4. Amgen Inc.
  • 18.5. Bristol-Myers Squibb Company
  • 18.6. Cipla Limited
  • 18.7. Eli Lilly and Company
  • 18.8. Entera Bio Ltd.
  • 18.9. FutureGen Biopharmaceutical (Beijing) Co., Ltd.
  • 18.10. GlaxoSmithKline PLC
  • 18.11. Ironwood Pharmaceuticals, Inc.
  • 18.12. Johnson & Johnson Services, Inc.
  • 18.13. Merck & Co., Inc.
  • 18.14. Morphic Therapeutic, Inc.
  • 18.15. Nestle S.A.
  • 18.16. OPKO Health, Inc.
  • 18.17. Pfizer Inc.
  • 18.18. Sanofi SA
  • 18.19. Sun Pharma Limited
  • 18.20. Takeda Pharmaceutical Company Limited
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. TScan Therapeutics, Inc.
  • 18.23. UCB S.A.
  • 18.24. Viatris Inc.
  • 18.25. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADVANCED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME MODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME MODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME MODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTEGRIN RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTEGRIN RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTEGRIN RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTERLEUKIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTERLEUKIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTERLEUKIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMINOSALICYLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AMINOSALICYLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMINOSALICYLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SURGICAL PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SURGICAL PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SURGICAL PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OSTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RESECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RESECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STRICTUREPLASTY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STRICTUREPLASTY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STRICTUREPLASTY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RECTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PARENTERAL PREPARATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PARENTERAL PREPARATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PARENTERAL PREPARATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EXTENDED RELEASE TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EXTENDED RELEASE TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EXTENDED RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CROHNS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CROHNS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CROHNS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INDETERMINATE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INDETERMINATE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INDETERMINATE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADULT POPULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADULT POPULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADULT POPULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GERIATRIC POPULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GERIATRIC POPULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GERIATRIC POPULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEDIATRIC POPULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEDIATRIC POPULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEDIATRIC POPULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 243. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 245. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. GCC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 285. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 287. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 288. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 295. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. G7 INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 298. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 300. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 303. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 305. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 308. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 310. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. NATO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES INFLAMMATORY BOWEL DISE